Quanterix

Quanterix is digitizing biomarker analysis to advance the science of precision health. Our digital health solution Simoa is changing the way healthcare is provided by enabling the detection and quantification of biomarkers previously difficult or impossible to measure to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for applications in a majority of therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease.

Quanterix to Launch High-Sensitivity Benchtop Instrument and Assays for Multiplex Biomarker Detection

Boston, MA and Washington D.C. - August 15, 2017 -- Quanterix Corporation, a company dedicated to digitizing biomarker analysis with the goal of advancing the science of precision health, today announced it will be expanding its single molecule array, or Simoa, technology platform portfolio to include the new Quanterix SR-Plex benchtop instrument. In the same...

Quanterix to Launch High-Sensitivity Benchtop Instrument and Assays for Multiplex Biomarker Detection

Quanterix Corporation, a company dedicated to digitizing biomarker analysis with the goal of advancing the science of precision health, today announced it will be expanding its single molecule array, or Simoa, technology platform portfolio to include the new Quanterix SR-Plex benchtop instrument. In the same way that the fully automated HD-1 Analyzer offers detection and...

Quanterix‚Ä™ CEO to Host Webinar on the Importance of Biomarkers for the Transformation of Precision Health

Lexington, Mass. - June 21, 2017 - Quanterix Corporation, a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its CEO and Chairman, Kevin Hrusovsky, will be hosting a webinar on the use of ultrasensitive biomarker assays to enable precision health, with a specialty focus on concussion...

Quanterix Launches the First Comprehensive Multiplex Panel to Study Traumatic Brain Injury Severity

LEXINGTON, Mass. ó May 17, 2017 ó Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, today announced the launch of the Simoa™ Neurology 4-Plex A assay (N4PA). The Simoa N4PA assay is the first test that can simultaneously measure four protein biomarkers from either cerebrospinal fluid (CSF) or directly...
113 Hartwell Ave, Lexington, MA 02421

617-301-9400